• Olga V. Zhukova Nizhny Novgorod State Medical Academy, Russia
  • Tatjana M. Konyshkina Nizhny Novgorod State Medical Academy
  • Svetlana V. Kononova Nizhny Novgorod State Medical Academy


Fishburne method, Acute obstructive bronchitis, Recurrent obstructive bronchitis, Analysis of cost-effectiveness, Antibiotic


Objective: This study was performed in order to estimate clinical effectiveness of antibiotic therapy in acute and recurrent obstructive bronchitis. For estimation the following was used: the Fishbern method of antibiotics distribution according to clinical effectiveness levels with the help of weighted coefficients and classical cost–efficiency†pharmacoeconomic analysis of the given antibiotic therapy. Then, for the first time ever, the obtained results of both methods were combined.

Methods: Materials were presented by the data on antibiotic therapy, given for patients who were hospitalized to the in-patient medical facilities due to acute or recurrent obstructive bronchitis. Medical records of 2 259 patients were included in the study. The patients were 0 to 18 y old. In order to determine the weighed coefficients of each used antibiotic with subsequent distribution according to the levels of clinical effectiveness the Fishbern method was applied. Three levels of clinical effectiveness were used in this study, i.e. high, medium and low. The cost–efficiency†pharmacoeconomic analysis was applied to combine costs and efficiency of the compared therapy courses in acute and recurrent obstructive bronchitis.

Results: Finally we found out that the highest probability of positive effect of cephalosporins group agents was associated with the use of Cefotaximum. (Biosynthesis). From the pharmacoeconomic point of view the most effective in treating acute and recurrent obstructive bronchitis in children in the in-patient facilities was Ceftriaxonum (Synthesis). Out of protected penicillins group, we used Amoxicillin/clavulanic acid–original drug Augmentin (Smithkline Beecham Pharmaceuticals) and generic drug Amoxiclav (Lek d. d). Augmentin effectiveness was 0.591, and Amoxiclav effectiveness–0.530. Cost of Augmentin treatment course was 106.26 rub. (1.68 US$), cost of Amoxiclav treatment course–103.50 rub.(1.63 US$). Augmentin use turned out to be the most reasonable. Augmentin treatment course was characterized by lower ICER coefficient versus Amoxiclav. We found out that from the pharmacoeconomic point of view Azitromicin (Vertex Ltd.) treatment turned out to be the most reasonable of the whole macrolides antibiotics for treatment of acute and recurrent obstructive bronchitis. However, according to the Fishbern clinical effectiveness classification this antibiotic belonged to the group with medium effectiveness level. The group with high effectiveness level included Sumamed, Azitral, Hemomicin, Clacid, Zitrocin and Clabax. Clacid and Clabax were excluded during the pharmacoeconomic analysis. The highest value of ICER coefficient was obtained for Sumamed and made up 39,367.50 rub. (621.53 US$). The highest level of clinical effectiveness was characteristic for Sumamed as well. Besides Sumamed was an original drug of azitromicin. According to the obtained data Azitral and Hemomicin had the lowest values of ICER coefficient (1151.67 rub. (18.18 US$) and 1812.22 rub. (28.61 US$) respectively). Therefore based on the clinical economic analysis these medical agents turned out to be the most suitable.

Conclusion: The results of the pharmacoeconomic analysis showed that the most effective drugs in treatment of acute and recurrent obstructive bronchitis in children in in-patient facilities appeared to be the following: out of cephalosporins-Ceftriaxonum (Synthesis), out of protected penicillins-Augmentin (Smithkline Beecham Pharmaceuticals), out of macrolides-Azitromicin (Vertex Ltd.). According to the Fishbern classification, these drugs belonged to the group with medium level of effectiveness.



Download data is not yet available.


Mizernitskiy YuL, Sorokina EV. Modern approaches to the treatment of acute bronchitis in children. Trudnyy Patsient 2008;9:4–8.

Dietzsch HJ, Rupprecht E, Wunderlich P. Epidemiologic and bronchologic aspects of chronic bronchitis in childhood. Pediatr Pathol 1975;10:176–83.

Hahn D. Antichlamydial antimicrobial therapy for asthma. Arch Pediatr Adolesc Med 1995;149:219–21.

Stratchounski LS, Belousov YB. Antibiotic therapy. Practical Guide. Moscow: Borges; 2000.

Stratchounski LS, Kozlov SN. Modern antimicrobial chemotherapy. Guidelines for doctors. Moscow: Borges; 2002.

Belousov YB, Omelianovsky VV. Clinical Pharmacology of respiratory diseases. Guidelines for doctors. Moscow: Universe Publishing; 1996.

Sidorenko SV, Yakovlev SV. β-lactam antibiotics. Russ. Open Med J 1997;21:1363-81.

Long SS, Pickering LK, Prober CG. Principles and practice of pediatric infectious diseases. New York; 1997.

Jacobs MR, Felmingham D, Appelbaum PC, Grunrberg RN. The Alexander project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003;52:229-46.

White AR, Kaye C, Poupard J. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother 2004;53:3-20.

Yuk JH, Nightingale CH, Quintiliani R. Clinical pharmacokinetics of Ceftriaxone. Clin Pharmacokinet 1989;17:223-35.

Ursi D, Dirven К, Loens К. Detection of Mycoplasma pneumoniae in respiratory samples by real-time PCR using an inhibition control. J Microbiol Methods 2003;55:149-75.

Welti M, Jaton К, Altwegg М. Development of a multiplex real-time quantitative PCR assay to detect Chlamydia pneumoniae, Legionella pneumophila and Mycoplasma pneumonia in respiratory tract secretions. Diagn Microbiol Infect Dis 2003;45:85-95.

Klein RB, Huggins BW. Chronic bronchitis in children. Semin Res infect 1994;9:13-22.

Juao T, Johnston S. Association of Mycoplasma pneumoniae antigen with inicial onset of bronchial asthma. Respir Crit Med 1994;149:1348-53.

Kuroki H, Morozumi М, Chiba N, Ubukata К. Characterization of children with Mycoplasma pneumoniae infection detected by rapid polymerase chain reaction technique. J Infect Chemother 2004;10:65-7.

Tipirneni P. IgE antibodies to Mycoplasma pneumoniae in asthma and other atopic disease. Ann Allergy 1980;45:113-6.

Von Hertzen L. Chlamydia pneumoniae antibody in chronical obstructive lungs disease. Int J Epidemiol 1996;25:658-64.

Esposito S, Bosis S, Faelli N. Role of atypical bacteria and azithromycin therapy for children with recurrent respiratory tract infections. Pediatric Infectious Dis J 2005;24:438-46.

Mensa J, Trilla A, Tarello I. Treatment of atypical pneumonia with josamycin. Med Clin (Barc) 1989;92:285–7.

Amsden GW. Anti-inflammatory effects of macrolides an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005;55:10–21.

Hahn D. Antichlamydial antimicrobial therapy for asthma. Arch Pediatrics Adolescent Med J 1995;149:219–21.

Darkes MJM, Perry CM. Clarithromycin extended-release tablet: a review of its use in the managment of respiratory tract infections. Am J Respir Med 2003;2:175-201.



How to Cite

Zhukova, O. V., T. M. Konyshkina, and S. V. Kononova. “FISHBURNE’s METHOD AND THE CLASSICAL METHOD OF PHARMACOECONOMIC ANALYSIS IN THE EVALUATION OF ANTIBIOTIC TREATMENT OF ACUTE AND RECURRENT BRONCHITIS IN CHILDREN”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 7, no. 11, Nov. 2015, pp. 185-90,



Original Article(s)